Announcement PDF ASX Announcement 29 May 2023 Cleansing Notice under Section 708A of the Corporations Act Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (“Act”). The Company has today issued 33,588 fully paid ordinary shares upon the exercise of unlisted options at an exercise price of $0.18 per fully paid ordinary share (”Issued Shares”). In accordance with section 708A(5)(e) of the Act, the Company gives notice that: 1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act; 2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and section 674 of the Act; and 3. as at the date of this notice there is no information that is ‘excluded’ information within the meanings of section 708A(7) and 708A(8) of the Act, being information: a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of: i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or ii. the rights and liabilities attaching to the Securities. This announcement has been authorised for release by the Board. For further information, please contact: Dr Luke Reid Chief Executive Officer E: Luke.Reid@microba.com Simon Hinsley Investor / Media Relations E: simon@nwrcommunications.com.au T: +61 401 809 653 About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit: www.microba.com Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com